000121012 001__ 121012
000121012 005__ 20241125101128.0
000121012 0247_ $$2doi$$a10.1111/jgh.16033
000121012 0248_ $$2sideral$$a131249
000121012 037__ $$aART-2023-131249
000121012 041__ $$aeng
000121012 100__ $$0(orcid)0000-0001-5932-2889$$aLanas, Angel$$uUniversidad de Zaragoza
000121012 245__ $$aManagement of iron-deficiency anemia following acute gastrointestinal hemorrhage: A narrative analysis and review
000121012 260__ $$c2023
000121012 5060_ $$aAccess copy available to the general public$$fUnrestricted
000121012 5203_ $$aMany patients experiencing acute gastrointestinal bleeding (GIB) require iron supplemen-tation to treat subsequent iron deficiency (ID) or iron-deficiency anemia (IDA). Guidelinesregarding management of these patients are lacking. We aimed to identify areas of unmetneed in patients with ID/IDA following acute GIB in terms of patient management andphysician guidance. We formed an international working group of gastroenterologists toconduct a narrative review based on PubMed and EMBASE database searches (fromJanuary 2000 to February 2021), integrated with observations from our own clinical expe-rience. Published data on this subject are limited and disparate, and those relating topost-discharge outcomes, such as persistent anemia and re-hospitalization, are particularlylacking. Often, there is no post-discharge follow-up of these patients by a gastroenterolo-gist. Acute GIB-related ID/IDA, however, is a prevalent condition both at the time of hos-pital admission and at hospital discharge and is likely underdiagnosed and undertreated.Despite limited data, there appears to be notable variation in the prescribing of intravenous(IV)/oral iron regimens. There is also some evidence suggesting that, compared with oraliron, IV iron may restore iron levels faster following acute GIB, have a better tolerabilityprofile, and be more beneficial in terms of quality of life. Gaps in patient care exist inthe management of acute GIB-related ID/IDA, yet further data from largepopulation-based studies are needed to confirm this. We advocate the formulation ofevidence-based guidance on the use of iron therapies in these patients, aiding a more stan-dardized best-practice approach to patient care.
000121012 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000121012 590__ $$a3.7$$b2023
000121012 592__ $$a1.179$$b2023
000121012 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b40 / 143 = 0.28$$c2023$$dQ2$$eT1
000121012 593__ $$aGastroenterology$$c2023$$dQ1
000121012 593__ $$aHepatology$$c2023$$dQ2
000121012 594__ $$a7.9$$b2023
000121012 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000121012 700__ $$aAndrews, Jane M
000121012 700__ $$aLau, James
000121012 700__ $$aToruner, Murat
000121012 700__ $$aBromley, Susan E
000121012 700__ $$aGralnek, Ian M
000121012 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000121012 773__ $$g38, 1 (2023), 23-33$$pJ. gastroenterol. hepatol.$$tJournal of Gastroenterology and Hepatology (Australia)$$x0815-9319
000121012 8564_ $$s233563$$uhttps://zaguan.unizar.es/record/121012/files/texto_completo.pdf$$yVersión publicada
000121012 8564_ $$s2668967$$uhttps://zaguan.unizar.es/record/121012/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000121012 909CO $$ooai:zaguan.unizar.es:121012$$particulos$$pdriver
000121012 951__ $$a2024-11-22-11:58:13
000121012 980__ $$aARTICLE